Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Arshna Qureshi"'
Publikováno v:
Journal of Lipids, Vol 2018 (2018)
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modu
Externí odkaz:
https://doaj.org/article/38b1826394424f7585c462410c705f72
Autor:
Dhrubajyoti Bandyopadhyay, Arshna Qureshi, Sudeshna Ghosh, Kumar Ashish, Lyndsey R. Heise, Adrija Hajra, Raktim K. Ghosh
Publikováno v:
Journal of Lipids, Vol 2018 (2018)
The risk of cardiovascular disease has been reported to have a linear relationship with LDL levels. Additionally, the currently recommended LDL target goal of 70 mg/dl does not diminish the CV risk entirely leaving behind some residual risk. Previous
Externí odkaz:
https://doaj.org/article/a5d39f43038842c58a1b955f19d35347
Autor:
Arshna Qureshi, Debasish Chaudhury
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 10, Iss 3, Pp OD20-OD21 (2016)
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease and is usually diagnosed with the SLICC criteria. Here we report a case of SLE presenting as Herpes Zoster (HZ). She had presented with painful vesicular eruptions from 8th thoracic
Externí odkaz:
https://doaj.org/article/8d81d2a10bda4002b850433ebb0b95a7
Autor:
James D. Reynolds, Arshna Qureshi, Silvia Perez-Protto, Lin Zhu, Daniel J. Lebovitz, Samir Q Latifi, Jonathan S. Stamler, Mohamed K. Awad, Alfred Hausladen, Kenneth D. Chavin
Publikováno v:
Annals of Surgery. 274:e610-e615
Objective To determine if addition of the S-nitrosylating agent ethyl nitrite (ENO) to the preservation solution can improve perfusion parameters in pumped human kidneys. Background A significant percentage of actively stored kidneys experience eleva
Autor:
Arshna Qureshi, Britt Conroy, Amr Mahran, Ilaha Isali, Sherif A. El-Nashar, Adonis Hijaz, Mandy Neudecker, Ahmad O Khalifa, David Sheyn, Fredrick R. Schumacher
Publikováno v:
International Urogynecology Journal. 31:1-14
A contribution of genetic factors to the development of stress urinary incontinence (SUI) is broadly acknowledged. This study aimed to: (1) provide insight into the genetic pathogenesis of SUI by gathering and synthesizing the available data from stu
Autor:
Ilaha, Isali, Mohammed Adel Ali, Al-Sadawi, Arshna, Qureshi, Ahmad O, Khalifa, Mukesh K, Agrawal, Sanjeev, Shukla
Publikováno v:
International journal of cell biology and physiology. 2(1-2)
Growth factors play active role in cells proliferation, embryonic development regulation and cellular differentiation. Altered level growth factors promote malignant transformation of normal cells. There has been significant progress made in form of
Autor:
Lin, Zhu, Arshna, Qureshi, Mohamed, Awad, Alfred, Hausladen, Silvia, Perez-Protto, Samir Q, Latifi, Daniel J, Lebovitz, Kenneth, Chavin, Jonathan S, Stamler, James D, Reynolds
Publikováno v:
Annals of surgery. 274(6)
To determine if addition of the S-nitrosylating agent ethyl nitrite (ENO) to the preservation solution can improve perfusion parameters in pumped human kidneys.A significant percentage of actively stored kidneys experience elevations in resistance an
Autor:
Arshna Qureshi, Raktim K. Ghosh, Adrija Hajra, Kumar Ashish, Lyndsey R. Heise, Dhrubajyoti Bandyopadhyay, Sudeshna Ghosh
Publikováno v:
Journal of Lipids
Journal of Lipids, Vol 2018 (2018)
Journal of Lipids, Vol 2018 (2018)
The risk of cardiovascular disease has been reported to have a linear relationship with LDL levels. Additionally, the currently recommended LDL target goal of 70 mg/dl does not diminish the CV risk entirely leaving behind some residual risk. Previous
Publikováno v:
Reumatología Clínica. 13:224-226
A 24-year-old female presented with catatonia and symptoms suggestive of Depressive Disorder. She also gave history of undocumented low grade irregular fever. The patient was worked up to rule out any organic cause or psychiatric illness. However, fu
Publikováno v:
Journal of Lipids, Vol 2018 (2018)
Journal of Lipids
Journal of Lipids
PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modu